Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence

Executive Summary

New PBM management program aims to cut in half the projected increases in diabetes drug spending in 2017, improve patient adherence rates by 5%.

Advertisement

Related Content

A Look At Payers' Early Game Plans For Driving Biosimilar Use
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Expect AZ To Hike Byetta's Price Ahead Of Teva's Generic
Express Scripts’ Cost Cap For PCSK9s Applicable To Other Drugs, PBM Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel